JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB264711

Human CBLB knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

CBLB KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 6.

View Alternative Names

AI429560, AI851073, CBLB_HUMAN, Cas Br M (murine) ecotropic retroviral transforming sequence b, Casitas B lineage lymphoma b, Casitas B-lineage lymphoma proto-oncogene b, DKFZp686J10223, DKFZp779A0729, DKFZp779F1443, E3 ubiquitin-protein ligase CBL-B, EC 6.3.2.-, FLJ36865, FLJ41152, Nbla00127, RING finger protein 56, RNF56, SH3-binding protein CBL-B, Signal transduction protein CBL-B

2 Images
Western blot - Human CBLB knockout HeLa cell line (AB264711)
  • WB

Lab

Western blot - Human CBLB knockout HeLa cell line (AB264711)

Lanes 1-4 : Merged signal (red and green). Green - ab54362 observed at 130 kDa. Red - loading control, ab181602 observed at 37 kDa.

ab54362 Anti-CBLB antibody [246C5a] was shown to specifically react with CBLB in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab264711 (knockout cell lysate ab258342) was used. Wild-type and CBLB knockout samples were subjected to SDS-PAGE. ab54362 and Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-CBLB antibody [246C5a] (<a href='/en-us/products/primary-antibodies/cblb-antibody-246c5a-ab54362'>ab54362</a>) at 1/500 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

CBLB knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human CBLB knockout HeLa cell line (ab264711)

Lane 3:

CTLL-2 cell lysate at 20 µg

Lane 4:

MCF7 cell lysate at 20 µg

Predicted band size: 109 kDa

Observed band size: 130 kDa

false

Sanger Sequencing - Human CBLB knockout HeLa cell line (AB264711)
  • Sanger seq

Unknown

Sanger Sequencing - Human CBLB knockout HeLa cell line (AB264711)

Homozygous : 1 bp deletion in exon 6.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 6

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264711-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264711 Human CBLB knockout HeLa cell line", "number":"AB264711-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264711-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264711 Human CBLB knockout HeLa cell line", "number":"AB264711-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
CBLB
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CBLB also known as Cbl-b or Casitas B-lineage lymphoma-b is an E3 ubiquitin-protein ligase with a mass of approximately 120 kDa. CBLB is required for the regulation of protein degradation and is involved in transferring ubiquitin to target proteins. It is expressed in multiple tissues including the immune cells such as T cells and B cells. This protein contains several functional domains that facilitate interaction with other proteins allowing it to influence various signaling pathways.
Biological function summary

CBLB plays a critical role in immune regulation and is part of the ubiquitin-proteasome system. As a member of the CBL protein family it interacts with several other proteins to form a complex that determines its function. This complex mediates signal transduction and maintains immune homeostasis efforting its regulatory influence over immune cell activation and avoiding excessive immune responses.

Pathways

CBLB integrates into intracellular signaling involving the T-cell receptor (TCR) and B-cell receptor (BCR) pathways. It modulates downstream signaling by finetuning protein levels and activity interfacing with related proteins such as ZAP70 and Syk. By controlling signal thresholds it ensures proper immune responses and prevents autoimmunity maintaining the balance in signal transduction processes.

Altered CBLB activity is associated with autoimmune diseases and certain cancers such as lymphoma. Its dysfunction can lead to improper regulation of immune responses allowing for unchecked immune activation or proliferation of cancer cells. CBLB interacts with other critical proteins like ITK in T cells influencing the development or progression of these diseases by affecting cell signaling dynamics. Understanding CBLB's role could support therapeutic interventions to modulate immune responses effectively.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com